Control of Atm−/− thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone Xianghong KuangMingshan YanPaul K. Y. Wong Original Article 27 November 2004 Pages: 203 - 212
Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors Frank RichardsonChris BlackRaymond Bendele Original Article 16 November 2004 Pages: 213 - 221
Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system Katsuhito NagaiKazuki NagasawaSadaki Fujimoto Original Article 04 November 2004 Pages: 222 - 230
Magnesium and potassium homeostasis during cisplatin treatment H. LajerM. KristensenG. Daugaard Original Article 14 October 2004 Pages: 231 - 236
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies Xueyu ChenRobert R. BiesMerrill J. Egorin Original Article 19 October 2004 Pages: 237 - 243
Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible? Katel MarignyFabienne AubinVirginie Gandemer Original Article 04 November 2004 Pages: 244 - 250
Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-α and translocating PKC-δ Xian-Ming ZhangJia ChenQiang Xu Original Article 05 November 2004 Pages: 251 - 262
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours Nadja E. SchoemakerI. E. L. M. KuppensJan H. M. Schellens Original Article 16 November 2004 Pages: 263 - 270
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study M. SchenaC. BaroneO. Bertetto Original Article 16 November 2004 Pages: 271 - 276
Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines Zhenfeng DuanDiana E. LamendolaMichael V. Seiden Original Article 24 November 2004 Pages: 277 - 285
DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells Hua-Rui LuLing-Hua MengJian Ding Original Article 16 November 2004 Pages: 286 - 294
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck Matthew M. CooneyKou-Yi TserngScot Remick Clinical Trial Report 06 November 2004 Pages: 295 - 300
Oxaliplatin activity in head and neck cancer cell lines Magali EspinosaMoises MartinezJorge Meléndez-Zajgla Short Communication 21 October 2004 Pages: 301 - 305
